ESTRO President-Elect: Insights and vision on the role of proton therapy in modern oncology скачать в хорошем качестве

ESTRO President-Elect: Insights and vision on the role of proton therapy in modern oncology

Prof. Barbara Alicja Jereczek-Fossa, Chair of Radiation Oncology at the European Institute of Oncology (IEO) in Milan, Italy, full Professor at the University of Milan, and President-Elect of ESTRO, discusses the transformative impact of proton therapy on patient care, institutional growth, and the future of radiotherapy. She outlines why IEO chose to add proton therapy, with ProteusONE, to broaden the treatment options for challenging, sensitive, and pre-treated tumors, and how it “provides very precise treatments for difficult tumors near sensitive structures.” She describes the dual benefits of proton therapy: offering patients lower acute and long-term toxicity while creating a “halo effect” that attracts research collaborations and referrals across all oncology services. Dr. Jereczek-Fossa explains that IEO selected IBA’s ProteusONE for its compact, scalable design, user-friendly workflow, and the reliable, hands-on support that ensured seamless integration from training through commissioning. She advocates the supine treatment position for patient comfort, reproducibility, and precision, and shares how an IBA on-site team enabled the IEO team to focus on clinical care rather than technical challenges. She also highlights a landmark case: a difficult-to-treat 27-year-old man with a skull-base tumor treated with proton therapy, showing symptoms improvement. Dr. Jereczek-Fossa emphasizes three pillars for proton therapy success—teamwork, intensive on-site and external training, and a robust referral system. She also issues a global call to action: increasing access, funding, research, and multidisciplinary education to ensure proton therapy reaches the estimated 15–20% of radiotherapy candidates who could benefit from it. Key Highlights 00:17 Introduction: Roles at University of Milan, IEO & ESTRO 00:38 Why Proton Therapy: precision for difficult tumors near critical structures 01:20 Benefits for patients and institutions: halo effect and & institutional growth 02:07 Why IBA and ProteusONE: reliability, compact design & scalability 03:06 Treating patients in supine vs upright: advantage of the supine, relaxed position 03:38 Training and seamless integration: precious on-site IBA support 04:28 Real patient impact with ProteusONE beam quality 05:22 Keys to success: teamwork, training & referral system 06:50 Perspectives as an ESTRO president: a need to improve access, research funding & proton therapy training ESTRO: European Society for Radiotherapy and Oncology 📚 Want to know more about IBA Proton Therapy? Take a closer look here: https://www.iba-protontherapy.com/ #ProtonTherapy #RadiationTherapy #ProteusONE #ProtonTherapyCenter #ProtonCenter #PatientCare #RadiationOncology #RadiationOncologist # EuropeanInstituteofOncology #IEO #ESTRO #IBAPartnership #MedicalPartnership #MedicalCollaboration #DifficultTumors #SupinePosition #ReferralSystem #PTtraining Disclaimer: The statements of the healthcare professional included in this testimonial reflect only her opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom she is affiliated or IBA. ▬ Learn more ▬▬▬▬▬▬▬▬▬▬▬ Selecting the right partner in Proton Therapy: Dr. Arie Dosoretz’s view    • Selecting the right partner in Proton Ther...   Moffitt’s Proton Therapy journey: partnering with IBA for today and tomorrow    • Moffitt’s Proton Therapy journey: partneri...   Supine vs. Upright: the best positioning for proton therapy, according to Dr. Dosoretz    • Supine vs. Upright: the best positioning f...   ▬ Follow us ▬▬▬▬▬▬▬▬▬▬▬▬ Discover us on LinkedIn:   / iba-proton-therapy   Find us on Facebook:   / ibatoday   Subscribe to this YouTube channel:    / @ibaprotontherapy   ▬ About IBA ▬▬▬▬▬▬▬▬▬▬▬▬ IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance."